GlassScriptPhysician profile
Ashley Mattix
NPI 1225647209
$2,983.68
in general payments reported to CMS, 2019-2025
23 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $248 · 2023: $426 · 2024: $1,204 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.73 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $353.62 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $275.60 | 2024-2025 | Tremfya |
| Madrigal Pharmaceuticals | $229.27 | 2025 | Rezdiffra |
| Genzyme Corporation | $218.79 | 2022-2025 | |
| Medtronic, INC. | $199.20 | 2022-2024 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.97 | 2022-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $117.78 | 2024 | Tremfya |
| Novo Nordisk INC | $89.46 | 2022 | |
| Gilead Sciences, INC. | $57.41 | 2025 | Livdelzi |
| Lilly USA, LLC | $55.73 | 2025 | Omvoh |
| Ardelyx, INC. | $49.69 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $35.71 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $28.88 | 2023-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $28.12 | 2022-2023 | Dificid |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcresta Therapeutics, INC. | $26.69 | 2024 | Relizorb |
| Celgene Corporation | $24.52 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $23.29 | 2024 | Bylvay |
| Redhill Biopharma INC. | $22.83 | 2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $19.27 | 2023 | |
| Ferring Pharmaceuticals INC. | $18.15 | 2023 | Clenpiq |
| Pfizer INC. | $16.40 | 2025 | |
| Intercept Pharmaceuticals, INC. | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mattix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.